MedTrace Logo

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

NCT05403385 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-08-03

No results posted yet for this study

Summary

The study will first determine the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed after receiving first line anti-PD(L)1 treatment for locally advanced or metastatic non-small cell lung cancer. The efficacy and safety of the combination is then compared to standard of care carboplatin and pemetrexed in the same populations.

Conditions

  • Metastatic NSCLC - Non-Small Cell Lung Cancer
  • Locally Advanced NSCLC - Non-Small Cell Lung Cancer

Interventions

DRUG

inupadenant

Adenosine 2a receptor antagonist

DRUG

Placebo

matched placebo capsule to inupadenant

DRUG

Carboplatin

standard of care chemotherapeutic, alkylating agent

DRUG

Pemetrexed

standard of care chemotherapeutic, anti-metabolite

Sponsors & Collaborators

  • iTeos Belgium SA

    collaborator INDUSTRY

  • iTeos Therapeutics

    lead INDUSTRY

Principal Investigators

  • Iteos Clinical Trials · iTeos Belgium SA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-26
Primary Completion
2025-06-13
Completion
2025-10-31
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Canada
  • Czechia
  • France
  • Italy
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05403385 on ClinicalTrials.gov